Intervertebral disc degeneration: A focus on obesity and type 2 diabetes

Diabetes Metab Res Rev. 2020 Jan;36(1):e3224. doi: 10.1002/dmrr.3224. Epub 2019 Nov 16.

Abstract

Obesity (OB) and type 2 diabetes (T2D) are among the most prevalent metabolic diseases. They currently affect a substantial part of the world population and are characterized by several systemic co-morbidities, including cardiovascular diseases, stroke, cancer, liver steatosis, and musculoskeletal disorders, by increasing the risk of developing osteoarthritis and intervertebral disc degeneration (IVDD). IVDD is a chronic, progressive process whose main features are disc dehydration, loss of disc height, and changes of load distribution across the spine, resulting in disc structure disruption and leading to low back pain onset. Given the high prevalence of these metabolic disorders and their association with IVDD, several studies have been conducted in order to investigate the causative role of biological and biomechanical characteristics proper to these conditions in the development of IVDD. This review aims to analyse the role of OB and T2D on IVDD, in order to clarify the pathophysiological drivers of the degenerative process and to delineate possible targets to which appropriate treatments may be addressed in the near future.

Keywords: intervertebral disc degeneration; low back pain; metabolic disease; obesity; type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / complications*
  • Humans
  • Intervertebral Disc Degeneration / etiology*
  • Intervertebral Disc Degeneration / pathology
  • Obesity / physiopathology*
  • Prognosis